Key result
Apixaban shows ~8% lower stroke risk vs warfarin, with consistent effects across liver subgroups.
Why the study?
Atrial fibrillation and chronic liver disease frequently coexist, but high-quality data on the safety and efficacy of apixaban versus warfarin for stroke or systemic embolism prevention in this population remain limited.
RCT (n=18,201)
Yes
Answers are grounded in this paper and cite their sources.
Chronic liver disease signals higher bleeding risk in anticoagulated AF; leaves open optimal agent selection in this subgroup pending dedicated trials.
Introduction Atrial fibrillation (AF) and chronic liver disease (CLD) frequently coexist; however, high-quality data on the use of apixaban for stroke or systemic embolism prevention in this population remain limited. We aimed to evaluate the safety and efficacy of apixaban compared with warfarin in patients with AF and CLD1. Methods While patients with AST or ALT > 2X or total bilirubin ≥ 1.5X the upper limit of normal were excluded from enrollment in ARISTOTLE, 511 patients had CLD as defined by site investigators, 2,314 had elevated hepatic enzymes at enrollment defined as AST > 41 U/L or ALT > 39 U/L or total bilirubin > 1.5 mg/dL, and 15,376 had neither CLD nor elevated hepatic enzymes.2 We conducted a secondary analysis to evaluate efficacy and safety outcomes by liver disease status and to assess treatment effects within these baseline subgroups. Results After multivariable adjustment, patients with CLD, compared with those without CLD, had no significant difference in stroke or systemic embolism (HR 0.92, 95% CI 0.46–1.85; p=0.96) or ISTH major bleeding (HR 0.56, 95% CI 0.25–1.24; p=0.20), but had a higher risk of any bleeding (HR 1.35, 95% CI 1.11–1.64; p=0.001). Patients with elevated hepatic enzymes did not differ from those without CLD in stroke or systemic embolism (HR 1.13, 95% CI 0.81–1.58; p=0.65), ISTH major bleeding (HR 0.89, 95% CI 0.66–1.19; p=0.58), or any bleeding (HR 1.03, 95% CI 0.93–1.14, p=0.81). When comparing the treatment effect of apixaban versus warfarin across liver disease subgroups, there was no statistically significant interaction for any efficacy or safety endpoints (all p ≥ 0.08; Figure 1). Conclusion In this secondary analysis of the ARISTOTLE trial, CLD was associated with an increased risk of any bleeding events, but this was not observed in patients with elevated hepatic enzymes. The treatment effect of apixaban versus warfarin on clinical outcomes did not differ by presence of CLD or elevated hepatic enzymes. These findings provide important reassurance regarding the use of apixaban in patients with mild CLD or mildly elevated hepatic enzymes.
No takes yet. Share an insight, caveat, or question.
Suleiman et al. (2026) conducted an RCT in Atrial fibrillation and chronic liver disease or elevated hepatic enzymes (n=18,201). Apixaban vs. Warfarin was evaluated on Stroke or systemic embolism (HR 0.92, 95% CI 0.46-1.85, p=0.96). Chronic liver disease increased any bleeding risk, while apixaban vs warfarin effects did not differ across liver subgroups.
Synapse has enriched 10 related papers. Consider them for comparative context: